摘要
In a recent paper published in Nature Biotechnology,Chen et al.1 describe a multiplex oncolytic virus platform that coupled with adoptive T cell therapy could solve the problem of repeat,systemic delivery of virus based therapeutics.It is widely accepted that multi-targeted therapeutic approaches attacking several facets of cancer biology are necessary to effectively deal with the tumor heterogeneity that exists within and between patients.
基金
C.S.I.and J.C.B.are supported by the Canadian Cancer Society Research Institute(CCSRI)and the Canadian Institutes of Health Research(CIHR).
